XenoPort to Release Second Quarter Financial Results on August 6
SANTA CLARA, Calif. -- July 30, 2013
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its second
quarter financial results on August 6, 2013 at approximately 4:30 p.m. Eastern
Time. The company will host a conference call at 5:00 p.m. Eastern Time that
same day. A replay of the call will be available for one week following the
To access the conference call via the Internet, go to www.XenoPort.com. Please
join the call at least 15 minutes prior to the start to ensure time for any
software downloads that may be required.
To access the live conference call via phone, dial 888-275-3514. International
callers may access the live call by dialing 706-679-1417. The reference number
to enter the call is 25662889.
The replay of the conference call may be accessed that same day after 8:00
p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at
855-859-2056 for domestic callers, or 404-537-3406 for international callers.
The reference number to enter the replay of the call is 25662889.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant^® (gabapentin
enacarbil) Extended-Release Tablets is approved and being marketed in the
United States by XenoPort. Regnite^® (gabapentin enacarbil) Extended-Release
Tablets is approved and being marketed in Japan by Astellas Pharma Inc.
XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's
pipeline of product candidates includes potential treatments for patients with
relapsing-remitting multiple sclerosis, psoriasis, spasticity related to
spinal cord injury and Parkinson's disease.
XENOPORT, Horizant and Regnite are registered trademarks of XenoPort, Inc.
Jackie Cossmon, 408-616-7295
Press spacebar to pause and continue. Press esc to stop.